Open Source Drug Discovery in Practice: A Case Study by Årdal, Christine & Rottingen, John-Arne
 
Open Source Drug Discovery in Practice: A Case Study
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Årdal, Christine, and John-Arne Røttingen. 2012. Open source
drug discovery in practice: A case study. PLoS Neglected Tropical
Diseases 6(9): e1827.
Published Version doi:10.1371/journal.pntd.0001827
Accessed February 19, 2015 11:50:04 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10587996
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAOpen Source Drug Discovery in Practice: A Case Study
Christine A ˚rdal
1*, John-Arne Røttingen
2,3
1Section for Global Health, The Norwegian Knowledge Centre for the Health Services, Oslo, Norway, 2Department of Health Management and Health Economics,
Institute for Health and Society, University of Oslo, Oslo, Norway, 3Department of Global Health and Population, Harvard School of Public Health, Boston, Massachusetts,
United States of America
Abstract
Background: Open source drug discovery offers potential for developing new and inexpensive drugs to combat diseases
that disproportionally affect the poor. The concept borrows two principle aspects from open source computing (i.e.,
collaboration and open access) and applies them to pharmaceutical innovation. By opening a project to external
contributors, its research capacity may increase significantly. To date there are only a handful of open source R&D projects
focusing on neglected diseases. We wanted to learn from these first movers, their successes and failures, in order to
generate a better understanding of how a much-discussed theoretical concept works in practice and may be implemented.
Methodology/Principal Findings: A descriptive case study was performed, evaluating two specific R&D projects focused on
neglected diseases. CSIR Team India Consortium’s Open Source Drug Discovery project (CSIR OSDD) and The Synaptic
Leap’s Schistosomiasis project (TSLS). Data were gathered from four sources: interviews of participating members (n=14), a
survey of potential members (n=61), an analysis of the websites and a literature review. Both cases have made significant
achievements; however, they have done so in very different ways. CSIR OSDD encourages international collaboration, but its
process facilitates contributions from mostly Indian researchers and students. Its processes are formal with each task being
reviewed by a mentor (almost always offline) before a result is made public. TSLS, on the other hand, has attracted
contributors internationally, albeit significantly fewer than CSIR OSDD. Both have obtained funding used to pay for access to
facilities, physical resources and, at times, labor costs. TSLS releases its results into the public domain, whereas CSIR OSDD
asserts ownership over its results.
Conclusions/Significance: Technically TSLS is an open source project, whereas CSIR OSDD is a crowdsourced project.
However, both have enabled high quality research at low cost. The critical success factors appear to be clearly defined entry
points, transparency and funding to cover core material costs.
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Introduction
The vast majority of drug research and development (R&D)
performed globally is directed towards the needs of high-income
countries [1]. The former Global Forum for Health Research and
the work that led to its establishment asserted that 90% of all
health R&D investment is spent on areas that concern only 10%
of the world’s population [2–4]. High-income countries have the
resources to pay, either publicly or privately, a price which gives
the innovator a profitable return on investment. The problem, of
course, is that the medical needs of high-income countries are not
the same as low-income countries. There are a host of diseases
that are primarily endemic to low-income countries, diseases like
dengue fever, malaria and schistosomiasis. Incentivizing R&D
investments by standard incentives like patents simply does not
produce the greatly needed, new medicines or diagnostics for
these diseases (which are often labeled ‘‘neglected’’). These are
neglected because the market does not offer sufficient purchasing
power. This market failure is an internationally recognized
problem and has been a major focus of the World Health
Organization (WHO).
In 2003 a Commission on Intellectual Property Rights,
Innovation and Public Health was established under the auspices
of WHO in order to apprise appropriate funding and incentive
mechanisms for these neglected diseases. A number of initiatives
have resulted from the Commission’s recommendations including
the formation of an expert working group to suggest and evaluate
options to incentivize R&D for these diseases [5]. A large variety of
financing and coordinating mechanisms have been proposed. One
that has received some support is open source drug discovery.
Open source drug discovery is a model based upon the open
source movement within the computer software industry. Basically
it takes two primary attributes, namely the collaboration of
volunteers and free access to the results, and applies them to drug
discovery. This should ultimately translate into new drugs entering
the market at prices determined by generic competition.
The concept has been discussed within the academic literature
for almost a decade. One of the first proposals by Maurer, Rai and
Sali [6] laid out the concept and applied it particularly to tropical
diseases. Subsequently, there have been several high-level
descriptions of example projects [7,8] and more recently, empirical
examples [9] of models, methods, processes and tools. However,
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definition of the concept. This combined with the multitude of
titles given to the concept (e.g. precompetitive collaboration, data
sharing, open access R&D, etc.) makes a common understanding
difficult.
Luckily, the non-profit research organization, Results for
Development Institute (‘‘R4D’’), has recently undertaken a high-
level review of open source drug discovery projects aimed at
neglected diseases [10]. One of the results of this review is a
straightforward definition. R4D defines a set of attributes that a
project must comply with in order to be considered open source:
1. The project’s data must be open access, meaning that anyone
can view the data free-of-charge.
2. The project must provide a forum for open collaboration
(across organizational and geographical boundaries).
3. The project must be governed by a set of rules that mandates
the project’s ‘‘openness’’.
If a project adheres to all three requirements, the resulting
advantages should be: verified content, collaborative projects, the
creation of a commons of knowledge and reduced costs for the
project (resulting in lower prices for the end product).
In an open source project data is made publicly-available for
anyone and everyone to verify. In drug discovery this means that
all virtual and laboratory results are published with as much of the
raw data available as possible. This should include enough data for
someone knowledgeable in the topic to review and critique the
data.
Collaboration across organizational and geographical bound-
aries offers several benefits. If enough researchers can be
incentivized to collaborate, even small contributions by many
researchers can significantly progress a project. It also opens a
project to new external ideas and approaches. It is anticipated that
the majority of the researchers will contribute on a volunteer basis,
thereby reducing the cost of the project.
A commons of knowledge is knowledge that is owned by the
public, meaning that there is no individual owner. All sciences
contain vast commons of knowledge. For example, in mathemat-
ics, algebra, geometry and calculus are all a part of the commons
of knowledge. No one owns them; they are public knowledge.
These knowledge commons grow when researchers place their
data in the public domain. This is most commonly done by
publishing the data without first patenting it. Knowledge residing
in the public domain may not be patented since novelty is required
to patent. This means that anyone can use, distribute and further
develop the research without paying a royalty to, or even notifying,
the innovator. If all the data necessary to manufacture a new drug
are placed in the public domain, anyone may undertake the
necessary regulatory steps for approval and begin to manufacture
the drug.
In open source computing it is more common to utilize
specialized licenses rather than the public domain since software
code is most commonly protected by copyright which is awarded
automatically. These licenses allow the innovator to maintain
some level of control over the innovation, generally ensuring that
attribution is given and that the code is freely accessible for anyone
to redistribute and modify. Any license in compliance with the
Open Source Definition [11] is considered open source. These
same aims can also be achieved by pairing a patent with a
standard license allowing free use of the patent so long as the use
adheres to a set of conditions. Examples include instances where
innovators allow patented medicines to be manufactured by
producers in low-income countries for local use only (i.e. equitable
licenses).
Project costs of open source projects are significantly reduced
based upon the percentage of work performed by volunteers as
well as the absence of the administrative costs that accompany
contract creation and royalty payment. Since the research is
placed in the public domain, the price of the manufactured
product is essentially de-linked from the cost of the R&D.
Manufacturers set a price point based solely upon their own costs
and expectations of the market’s willingness to pay. Ideally generic
competition is introduced immediately.
Three similar concepts (open access, open innovation and
crowdsourcing) are often confused with open source. Open access
means that anyone can view, copy or distribute some form of
content (e.g. an article, book, etc.) free-of-charge; it does not
permit changing the content [12].
Open innovation is simply the use of external sources of R&D
[13]. This may include paying royalties to the innovator and does
not necessitate any type of transparency or commons formation
and is therefore not related to the general ‘‘open definition’’. For
example, AstraZeneca recently agreed that a certain set of external
scientists could access all of the data related to approximately 20
experimental drugs that they have stopped researching. This data
is not open to the public. These drugs are under patent, and
AstraZeneca will commercially benefit if the scientists manage to
determine a profitable use of these molecules [14]. Open
innovation offers the potential benefits of collaborative projects
and reduced costs of both the project and the end product, but
does not offer verified content or the creation of a commons of
knowledge.
‘‘Crowdsourcing’’ is the use of volunteers to perform a specified
task, generally through an open call [15]. For example, the FoldIt
game has players fold proteins into their most chemically stable
configuration, introducing new possibilities to the scientists who
gather and research the players’ efforts [16]. The contributors do
not own their output, and crowdsourced outputs may or may not
be protected by intellectual property rights. Crowdsourcing offers
the same benefits of open innovation - collaborative projects and
reduced costs of both the project and the end result, but does not
necessarily offer verified content or the creation of a commons of
knowledge.
Author Summary
Open source drug discovery can be an influential model
for discovering and developing new medicines and
diagnostics for neglected diseases. It offers the opportu-
nity to accelerate the discovery progress while keeping
expenditures to a minimum by encouraging incremental
contributions from volunteer scientists. Publishing raw
data and results in the public domain is positive within the
context of neglected diseases since it facilitates open
collaboration while obviating the ability to patent any
results. In this way it effectively de-links the research and
development costs from the sales price of the end
product, the new medicine or diagnostic. This case study
demonstrates that implementations of the open source
model can differ while still achieving the ultimate goal of
obtaining high quality research at reduced costs. However,
the importance of clearly defined entry points, transpar-
ency and funding are shared success factors. These
findings present the practical challenges of implementing
a theoretical concept and hopefully will assist other
scientists in organizing future open source drug discovery
projects.
Open Source Drug Discovery in Practice
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because it offers the opportunity to accelerate the discovery
progress while keeping expenditures to a minimum. Patents in
these instances are neither desired nor justifiable since the cost of
patenting will likely exceed any potential profits.
A current gap within the academic literature is detailed profiles
and evaluations of ongoing open source initiatives for neglected-
disease research. This is the objective of our case study – to learn
from the first movers of open source drug discovery, their successes
and failures, in order to generate a better understanding of how a
much discussed theoretical concept actually works in practice.
After a search for relevant cases, we have studied two cases in
detail: The Council for Scientific and Industrial Research Team
India Consortium’s Open Source Drug Discovery project (CSIR
OSDD) and The Synaptic Leap’s Schistosomiasis project (TSLS).
The objective of the case study is to answer the following
research questions:
N How do existing open source drug discovery initiatives attract
volunteers, create a collaborative model, achieve progress,
address the need for physical supplies and manage intellectual
property rights?
N What have these projects accomplished to date?
Our results demonstrate that open source drug discovery
initiatives can make significant achievements. However, there is
no one formula for success. Critical success factors are clearly
defined entry points, transparency and funding to cover all
material costs.
Methods
A case study was chosen to research open source drug discovery
projects in-depth in accordance with pre-defined research
questions. Yin [17] recommends a case study approach when
the researcher wants to answer ‘‘how’’ and ‘‘why’’ questions, when
an experiment is inappropriate or when it is necessary to
understand the context in greater detail. He categorizes case
studies as either explanatory (attempting to find the causality of a
specific case), exploratory (exploring an intervention with no clear
outcome) or descriptive (describing a real-life phenomenon and its
context). We decided to conduct a descriptive case study to
examine the real-life phenomenon of open source drug discovery
as it applies to neglected disease R&D.
Case Selection
We chose open source drug discovery projects targeted towards
neglected diseases that havehad at least one year of continuous data
from multiple individuals. We identified twelve potential cases of an
open source approach to drug discovery, mainly through our
ongoing research of the topic but also through other articles
reviewing the topic [8–10]. The potential cases identified along with
their conformance to the selection criteria are given in Table 1.
Two cases fit our selection requirements: The Council for
Scientific and Industrial Research Team India Consortium’s
Open Source Drug Discovery project (CSIR OSDD) and The
Synaptic Leap’s Schistosomiasis Project (TSLS). The other
potential cases were excluded either because the project’s
collaboration efforts were not viewable (meaning that data was
shared but the process of producing the data was not shared or
collaboratively performed) or the project was inactive (meaning
that a small number of individuals would occasionally make a
posting which was most often an interesting article about the
topic).
Data Collection
Data were gathered from four sources: an analysis of the cases’
websites, interviews of participating members, a survey of potential
members of CSIR OSDD and a literature review. Additionally the
project managers of both cases were sent our findings, and their
comments have been incorporated into this paper.
All websites of the two projects have been reviewed focusing on
aspects of collaboration and progress. The licenses have also been
reviewed to understand how intellectual property is managed.
Telephone and written interviews were performed from
November 2010 to April 2011. Interview content focused on
collaboration, intellectual property and progress. An interview
template was devised and reviewed by two external researchers
familiar with open source drug discovery (Annex S1). We posted
introductions to our case study on both the CSIR OSDD and
TSLS websites, asking interested individuals to e-mail us if
interested in participating. We also directly e-mailed participants
where we could find contact information (n=99). Fourteen (14)
individuals responded, representing both project leaders and active
members. Among the 14, only ten completed all interview topics
and this was disproportionately members of TSLS project (n=9).
The individual completing the interview from the CSIR OSDD
project had observed the project but not contributed. However,
four CSIR OSDD project members partially completed the
interview.
A survey (Annex S2) of potential members of the CSIR OSDD
project was performed in February and March 2011. The CSIR
OSDD project was selected because they are performing general
tuberculosis drug discovery activities where as the TSLS project is
performing a very specific development task in regards to making a
new synthesis of a known molecule, making it more difficult to
identify researchers with similar research interests. PubMed was
searched on January 31, 2011 for articles published within the last
year containing the phrase ‘‘Mycobacterium tuberculosis genome’’. A
second search was performed on February 10, 2011 for articles
published within the last year containing the phrase ‘‘Tuberculosis
drug discovery’’. The searches resulted in 221 and 112 articles
respectively. The corresponding author’s e-mail address was
retrieved from each of these articles and then duplicates were
removed. Sixty-one individuals completed the survey (n=46 from
the genome group and n=15 from the drug discovery group).
A literature review was performed to identify any academic
articles relevant to our research questions. This was done by
searching Google Scholar on December 6, 2011 with the following
strings, achieving the following results:
N ‘‘The Synaptic Leap’’+schistosomiasis (n=15)
N CSIR India ‘‘open source drug discovery’’ (n=48)
These articles were read.
Ethics Statement
We sought approval for our research portfolio (including
interviews and surveys) from the Norwegian Committees for
Medical and Health Research. The Committee decided that our
research did not require their ethical approval since we are
studying collaboration amongst scientists and not patients. With
that said, all interview participants were informed orally that their
interview responses would be treated confidentially and that their
participation was completely voluntary. Written consent was
deemed unnecessary since interview participants responded
individually to a call for interviews from a website posting. The
survey data were analyzed anonymously. The interview data were
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available websites.
Results
We evaluated the two cases in regards to four aspects:
accomplishments, process (including attracting volunteers, collab-
oration and addressing the need for physical supplies), manage-
ment of intellectual property, progress and funding. We will
present the two cases separately.
CSIR’s Open Source Drug Discovery Project
The Council for Scientific and Industrial Research Team India
Consortium’s Open Source Drug Discovery project (CSIR OSDD)
started in 2008 with an initial grant from the Government of India
of approximately US $35 million (of which US $12 million has been
released to date). Their vision is ‘‘to provide affordable healthcare to the
developing world by providing a global platform where the best minds can
collaborate & collectively endeavor to solve the complex problems associated with
discovering novel therapies for neglected tropical diseases like Malaria,
Tuberculosis, Leshmaniasis, etc.’’ Initially they have targeted tubercu-
losis as their primary research area (see Table 2).
Accomplishments
CSIR OSDD aims to discover novel therapies for tuberculosis.
Its activities are spread throughout every stage of the discovery
process (from drug target identification to lead optimization). It
has 54 molecules in process and has initiated discussions with
pharmaceutical companies regarding pre-clinical and clinical
trials. Its main achievements to date are: the re-annotation of
the Mycobacterium tuberculosis genome and the generation of 11
models for prediction of anti-tuberculosis activity [18].
The genome of the Mycobacterium tuberculosis strain H37Rv was
first published in 1998 [19]. Since publishing, new research has
been performed in such areas as gene functionality, associated
proteins, interactions and potential drug targets. Most of this
research is available electronically but on many different websites.
Data curation involves establishing and developing long-term
repositories of reference data [20]. The CSIR OSDD project
created a data repository for genome-level information regarding
the strain H37Rv, by recruiting volunteers to gather relevant
research articles, extract the data and transcribe it into a
standardized format. The aggregation of this process is TBrowse,
a publicly-available integrative genomics map, http://tbrowse.
CSIR OSDD.net/ [21]. The formation of TBrowse demonstrated
that students could successfully contribute to open source drug
discovery. With this proof of concept performed, CSIR OSDD
moved onto a more complex task called Connect to Decode,
annotating the tuberculosis genome. Again students collated the
data contained in published articles regarding the approximate
4,000 genes contained in the tuberculosis genome. For those genes
whose function was unknown, participants computationally
extrapolated the possible function(s). This work created a
metabolome (a complete set of small molecules involved in
growth, development and reproduction) and protein-protein
functional network for Mycobacterium tuberculosis that is being used
to identify potential drug targets. This data is contained on website
called Sysborg.
Eleven groups have worked independently to develop models
for prediction of anti-tuberculosis activity. Two of these models
have been published [22] and the other nine are in the process of
being written up. CSIR OSDD has purchased the virtual
screening data of 20,000 molecules, where 140 of these molecules
have shown promising anti-tubercular properties. CSIR OSDD
has built a new repository [23] (the OSDD Chemical Database) to
gather data on these and other promising molecules. As of
February 22, 2012, 304 molecules reside in the virtual repository,
submitted by 17 individuals. Four molecules have been screened
against tuberculosis, 14 against malaria.
To perform these accomplishments, CSIR OSDD has created a
significant amount of infrastructure. They utilize several websites
including:
N A publicly-available informational website (www.osdd.net) that
describes the project in general and gives links to the other
Table 1. Potential Cases for Inclusion.
Potential Case Collaboration Efforts Viewable Project Status Timeframe of Data
The Council for Scientific and Industrial Research
Team India Consortium’s Open Source Drug
Discovery project (CSIR OSDD)
Yes Active 2008 – Ongoing
Collaborative Drug Discovery No Active 2004 – Ongoing
Cambia’s Open Innovation No Inactive 2009
PATH’s Malaria Vaccine Initiative No Active 1999 - Ongoing
Structural Genomics Consortium No Active 2003 - Ongoing
The Pool for Open Innovation against Neglected
Tropical Diseases
No Inactive* 2009–2011
The Synaptic Leap’s Malaria Project Yes Inactive** 2006–2008
The Synaptic Leap’s Schistosomiasis Project (TSLS) Yes Active 2006 - Ongoing
The Synaptic Leap’s Toxoplasma Project Yes Inactive 2006–2007
The Synaptic Leap’s Tuberculosis Project Yes Inactive 2006–2007
Tropical Diseases Initiative No Active 2004 - Ongoing
TDR Targets No*** Active 2007 - Ongoing
*This project has been transformed to the WIPO Re:Search project.
**This project has been restarted in 2012 with a considerable amount of activity.
***TDR Targets does share posted lists. However, these are not collaboration efforts towards a designated goal.
doi:10.1371/journal.pntd.0001827.t001
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now forward.
N An online collaboration forum (http://sysborg2.osdd.net)
requiring a username and password to access any content.
This includes pages to enter and view ideas, projects,
laboratory notebooks and documents. A project management
system allows members to track tasks and progress. A forum
tracks all comments. A resources page allows participants to
request new biological or chemical materials as well as
financing. A community page allows members to group into
activity-related communities. Members can check that they
have received due credit on an attribution page. An eLearning
page links members to online tutorials to assist them with their
contributions. There is also social networking functions –
messaging, linking with friends, blogging and a calendar. We
will call this website ‘‘Sysborg’’ from now forward. This
website replaced a previous wiki-style website in 2010. The
content from this initial website is no longer accessible/
viewable. Users have expressed that the new Sysborg website is
more difficult to navigate and has technical problems. CSIR
OSDD is working on improving the website based upon the
users’ feedback.
N The publicly-available CRDD web portal (http://crdd.osdd.
net/) provides access to numerous drug discovery computing
tools throughout the phases of drug discovery (including target
identification, virtual screening and drug design) as well as the
OSDD Chemical Database.
N Several publicly-available forums (http://groups.google.com/
group/osdd-public, http://osddnews.blogspot.com/, http://
scienceopenscience.blogspot.com/, http://twitter.com/osdd)
which are used for general (non-task-related) discussions.
Process
According to a description of the project [24], the workflow
follows a standard process comprised of the following steps:
1. Projects or ideas are posted by any community member on
Sysborg.
2. The community then reviews the project/idea.
3. A principal investigator (mostly experienced scientists) will take
responsibility for the project/idea and secure any necessary
funding from CSIR OSDD.
4. The community collaborates on the project and produces
results (typically in the form of laboratory notebooks).
5. The results are made available on Sysborg for the community
to review. Members provide input on project monitoring and
quality control.
6. An unstated, but practiced, next step is that the results are
published in a peer-reviewed journal.
Step 0 - Logging onto the website. Before an individual can
browse Sysborg, he/she must register and await an automatically
generated password to log on. However, with these details a user
can only access the social functions of the website, not any of the
project data. The e-mail states, ‘‘Please note that the team will verify your
details and it takes approximately 2–3 working days to assign you necessary
permissions to access the portal content.’’ Once these permissions are
granted the user may access the majority of functionality within
Sysborg.
Step 1 - Posting a project or an idea to Sysborg. As of
November 30, 2011 there were 52 ideas and 139 projects posted
on Sysborg, although the reporting section of Sysborg states that
there are 99 ideas and 523 projects. We are uncertain if this means
that some content is hidden or that the reporting system is in error.
Projects typically include a problem description and work plan.
Most projects (92% as of December 6, 2011) have designated a
project manager. There are on average two members per project,
although 45% of projects have no project members. Projects may
be associated with comments, ideas, laboratory notebooks or other
projects. There is no status associated with a project so it is unclear
if a project is pending, in progress or completed. There is a link
within each project to a project management system, but this
system seems not to be in use.
Step 2 - Project review. The second procedural step is that
the community reviews the project. This appears to happen rarely
on Sysborg (however, the CSIR OSDD project management team
has informed us that many of the existing projects were reviewed
in the previous website but this review has not been migrated to
Sysborg). Out of 139 projects, 80 (58%) had no comments
associated with them. Ten projects (7%) had three or more
comments (with a median of four comments but one project with
34 comments).
Step 3 - Secure funding. The third step is that a project
manager will take responsibility for the project and secure any
necessary funding from CSIR OSDD. From the CSIR OSDD
website it appears that named institutions have responsibility for
tasks within the drug discovery process, e.g. National JALMA
Institute for Leprosy & Other Mycobacterial Diseases has
responsibility for identifying drug targets through biological
repositories and strains, the Institute of Genomics and Integrative
Biology in Delhi has responsibility for identifying drug targets
Table 2. CSIR’s Open Source Drug Discovery Project at a glance.
Focus: Tuberculosis medicines (all aspects of discovery and development)
Year started: 2008
Funding: INR 1.5 billion (,US $35 million), the Government of India
Number of contributors: 451
License: An original license, ‘‘OSDD Terms and Conditions’’
Achievements to date: (1) Curated a re-annotation of Mycobacterium tuberculosis genome which generated a metabolome and
protein-protein functional network to be used to identify potential drug targets (2) Generated 11 models
for prediction of anti-tuberculosis activity (3) Created a chemical repository of small molecules
Number articles publishing the project’s scientific findings: Five [21,22,38–40]
Evaluations/audits: None known
doi:10.1371/journal.pntd.0001827.t002
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institutions are encouraged to participate [18].
Before funding may be secured, a project must be peer
reviewed. After all questions from the peer-review have been
answered, the project and its budget are reviewed by a committee
of three specified individuals. If the committee recommends the
budget, the funds are released [25]. This peer review and approval
process is rarely visible in Sysborg; we found only two examples
where all activities were visible [26,27].
There is also an automated resources request process which
includes cash requests among other resources (e.g. genomic DNA
materials). This process appears to be rarely used.
Step 4 - Attracting contributors and collaborating. The
fourth step is that the community collaborates on the project and
produces results. As mentioned above, CSIR OSDD partners with
institutions that have specific responsibilities. Eight CSIR India
laboratories and 36 Indian universities and academic institutes
[28] were selected through a screening process including on-site
inspections [29]. Upon selection, it appears that the institutions
receive funding to cover the costs of equipment, chemicals and
consumables for CSIR OSDD contributors [30].
Researchers from these institutions become project managers,
leading and organizing activities. The Project Director contacts
project managers directly to instigate new activities, or project
managers may suggest new activities. Students and other
researchers are encouraged to participate through open calls for
contributions. Students reported through the interviews hearing
about CSIR OSDD through direct contact, the Internet and
word-of-mouth. Students also reported through the interviews that
they were highly motivated to help fellow Indians by finding cures
for tuberculosis. Learning new skills was also a motivation.
CSIR OSDD has published several articles detailing the aims of
the project [31,32], likely to draw attention to the project from
other tuberculosis researchers. We were curious to know if
tuberculosis researchers worldwide were aware of the project
and if they ever viewed the data. We surveyed the corresponding
authors (n=298) of all articles contained within PubMed,
published in the last year focused on either tuberculosis drug
discovery or Mycobacterium tuberculosis genome. We received 61
responses (20% response rate). Thirteen authors (or 21%) were
aware of TBrowse (the publicly-available integrative genomics
map) and of those seven had viewed TBrowse.
As of February 16, 2012 there were 5,444 users registered in
Sysborg. Of these, 451 had accrued points (as reported by CSIR
OSDD management). Points are awarded after the completion of
a specified task [33], however we could not find any data
specifying how the point value is calculated. By accruing points,
contributors can achieve higher levels of membership which gives
the contributor greater rights, privileges and responsibilities [34].
In some instances, contributors can receive monetary rewards
[33].
Students may need to apply to contribute to resource-
constrained activities. For example, in one project students have
applied and been selected to utilize grid-based supercomputing
facilities from their desktops. Before students are given access to
this facility, they must complete an application form and affidavit
stating that ‘‘all activities performed, including raw data and results would
be the property of the [CSIR OSDD] community to be shared with the
community and covered under the [CSIR OSDD] License Terms and
conditions of use.’’ [35] This application form is sent via e-mail to the
CSIR OSDD Technical Committee for approval with a copy sent
via surface mail. To train the students in using this functionality, a
three-day boot camp was held in Calicut for about 35 participants
where travel costs were paid for. The presentations from this boot
camp were filmed and placed on YouTube [36]. Additionally a
large amount of training materials have been made available on
Sysborg, in YouTube and a telephone-based help desk has also
been set up [26].
Project managers are not only responsible for recruiting
contributors but also creating assignments (sometimes with
deadlines), giving instruction, ensuring that the necessary facilities
and materials are present, performing quality assurance, and
following up that assignments are received [37]. Laboratory
notebooks contain the data for all laboratory tasks. There were
363 laboratory notebooks as of November 30, 2011. These
notebooks were largely consolidated to a few projects; five projects
had three or more lab notebooks with one project having 119.
Most projects (n=110 or 79%) had no associated laboratory
notebooks.
According to an interviewee, after each activity is completed, a
group meeting is held either face-to-face or via Skype to go
through the results and finalize the data. The final results are then
posted to Sysborg. This may explain why 95% of all laboratory
notebooks have no associated comments.
Step 5 - Peer-review of results. Results posted to Sysborg
are to be reviewed by the community as a part of quality control.
The CSIR OSDD website states that all project managers report
directly to the Project Director online, a core team meets monthly
and the chief mentor reviews the progress of the platform quarterly
along with the board of mentors [34]. We could find no evidence
on Sysborg of this review process.
Step 6 – Publishing. Lastly, project results may be published
in a peer-reviewed journal. Five articles [21,22,38–40] have been
published to date covering the results of the project’s collaborative
tuberculosis drug discovery activities, four of these in 2011 alone, a
significant achievement. CSIR OSDD has also published two
articles describing the CSIR OSDD process [31,32] and one
regarding tools [9]. The CSIR OSDD website also lists other
scientific publications that have received funding from CSIR
OSDD but are not the result of project collaboration [41–43].
Management of Intellectual Property
No content may be viewed on Sysborg without first logging on.
When registering, the user must accept the terms and conditions of
the CSIR OSDD license, a non-standard license written
specifically for the project [44]. The license affirms that CSIR
OSDD owns all content posted to Sysborg (13.1). Therefore,
content is not a part of the public domain. All improvements based
upon data within Sysborg must be contributed back to CSIR
OSDD under a worldwide royalty-free non-exclusive license
(13.5–6). There is no stipulation in the license that CSIR OSDD
must adopt non-exclusive licensing of the resulting products or any
stipulations regarding the final price of these products. However,
the mission states clearly that they aim ‘‘to make available affordable
medicines to every single person of the developing world.’’
Progress
CSIR OSDD has mapped out a process for discovering and
developing new tuberculosis medicines. They have 54 molecules in
the pipeline, including two candidates in the hit to lead phase
which are being optimized in collaboration with private partners
(which seem to follow the same overall process) [24]. They have
instigated talks with pharmaceutical industry to perform the
preclinical and clinical trials. Their approach to clinical trials is to
build facilities specifically for clinical trials within publicly-funded
hospitals. These trials would be conducted by CSIR OSDD in
combination with the hospital personnel and experts from private
pharmaceutical companies. All data will be made available
Open Source Drug Discovery in Practice
PLOS Neglected Tropical Diseases | www.plosntds.org 6 September 2012 | Volume 6 | Issue 9 | e1827(presumably anonymized) [24]. We found no evidence of clinical
trials on Sysborg so we presume that these are planning activities
in anticipation of forthcoming trials.
Funding
The government of India has committed to grant CSIR OSDD
INR 1.5 billion (or about US $35 million) of which US $12 million
has already been paid out [33]. These funds pay the administrative
costs of the project including equipment and material costs at the
partner institutions and the salaries of a few contributors. Most
work is done by unpaid volunteers. However, the project does hire
individuals at times to perform specific tasks. For example, 20
female scientists are planned (or have been) hired to work from
their homes for four hours a day [30]. Expert mentors are paid to
attend meetings [30]. Vacancies are regularly posted on the
website for paid positions such as project assistants [45].
The Synaptic Leap’s Schistosomiasis Project
The Synaptic Leap website was launched in 2006 with an aim
‘‘to provide a network of online research communities that connect and enable
open source biomedical research’’ [46]. It was launched with four pilot
disease research areas: malaria, schistosomiasis, toxoplasma and
tuberculosis. Each area had a project leader with the responsibility
of gathering and motivating international researchers to contribute
to the Synaptic Leap community by sharing results, giving
feedback and possibly undertaking new research tasks. Since
launch, the malaria, toxoplasma and tuberculosis communities
have been relatively silent. However, the schistosomiasis commu-
nity has consistently utilized the website to share findings, discuss
research results and identify new, necessary research tasks (see
Table 3).
Accomplishments
The aim of the TSLS project was a well-defined drug
development task – to generate the off-patent schistosomiasis
drug, praziquantel, as a single enantiomer. This would remove the
bitter taste of the original drug making it more palatable for
children as well as remove some of its side effects. This has been
needed for years but companies would not invest, likely because
the innovation was not suitably lucrative since an inexpensive drug
already existed. Additionally the patent on praziquantel expired in
the 1990s [47], and the needed change was likely not sufficiently
novel to warrant a new patent. The optimization of praziquantel
had long been a high priority of WHO which was affirmed in
TDR’s (Special Programme for Research & Training in Tropical
Diseases) Scientific Working Group on Schistosomiasis in 2005
and repeated in its Business Plan of 2008–2013. [48] This led to
the funding of the TSLS project in 2008 by both WHO and the
Australian government. The TSLS project completed this task in
2011.
To perform these accomplishments, TSLS has made use of web
tools that were already available such as The Synaptic Leap
website and an open source online laboratory notebook [49]. The
laboratory notebook was chosen because it allowed contributors to
enter scientific data more easily than The Synaptic Leap website.
Process
Dr. Matthew Todd became the leader of the schistosomiasis
project in 2006. He was already working on the problem of the
production of praziquantel as a single enantiomer but wanted the
project to go faster than typical academic speed. He thought that
open source might be a solution to attract industry participation.
The project was first discussed on the TSLS website in January
2006 [50]. However, even though Todd regularly updated the
website, there was little external interest shown in the project.
From 2006 to 2008 there were 35 postings initiated on the website,
with only four of these coming from individuals other than Todd.
In 2008 the project received their funding (although contracting
delays resulted in the laboratory work actually not starting until
January 2010). This allowed the project to hire a full-time
postdoctoral researcher and cover laboratory expenses for Ph.D.
students, mentored by Todd at the University of Sydney. This
gave the project some needed momentum. From project initiation
in 2006 until project funding in the beginning of 2010, 10% of
new postings were initiated from external contributors (those not a
part of Todd’s team at the University of Sydney). After the funding
was received 30% of postings were made by external contributors.
However, comments posted by external contributors did not vary
significantly (increasing only from 50% to 53%). At the time of
funding, significant external marketing efforts were also undertak-
en (see below).
The data from the on-going experiments were regularly posted
in the online publicly-available laboratory notebook [49] and
summarized on The Synaptic Leap, without peer review. Todd
did not want to slow the speed of sharing the data by
implementing an offline peer review process. He expected project
contributors to give the researchers feedback, and this turned out
to be the case. Key findings have received as many as 14
comments; entries average 1.5 comments each, with 50% of all
new postings receiving comments. This process has been an
adjustment for some of the contributors. There were concerns that
mistakes would be published with name attribution. One
researcher stated that he used more time to check his results
before publishing them online. Ultimately, Todd expected peer
Table 3. The Synaptic Leap’s Schistosomiasis Project at a glance.
Focus: Development of a low-cost synthesis of an existing schistosomiasis drug, praziquantel
Year started: 2006
Funding: AUS$315,000 (,US $330,000) Australian government and WHO
Number of contributors: 37
License: Scientific discoveries in the public domain and copyright according to the Creative Commons Attribution 2.5 License
Achievements to date: Produced the schistosomiasis drug, praziquantel, in enantiopure form
Number articles publishing the project’s
scientific findings:
One [52]
Evaluations/audits to date: None known
doi:10.1371/journal.pntd.0001827.t003
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rizing the results of this project have been published in September
and October 2011 (one with a focus on the project results and one
focused on the process) [51,52].
In order to make contributions as easy as possible, Todd
regularly posted an update on TSLS detailing progress and
descriptions of the next tasks needed [53,54]. This minimized the
time that potential contributors needed to sift through backdated
postings to come up to speed. It also avoided duplication of efforts.
The project did not have an official project plan or deadlines, but
it was time-constrained by funding parameters (three years).
Even after the postdoctoral researcher was hired to contribute,
there was a hope that greater external interest could be raised for
the project. Todd began giving speeches including a Google
TechTalk in April 2010 [55]. After each article, blog and
presentation, the project experienced significant increases in
website traffic [51]. It was also decided to reach out to a closed
chemistry networking forum on LinkedIn. This positively resulted
in 20 comments from 11 different scientists, new to the project,
and four private e-mails [51]. One of the respondents was a Dutch
contract research organization interested in participating in the
project [51]. This was an important milestone for the project
because the CRO had the equipment and expertise to perform
some of the necessary tasks very quickly (they completed tasks in
weeks as opposed to the months it would probably have otherwise
taken). This industry-academic support enabled the project to
complete the project before the funding ran out.
Ninety-seven (97) individuals have registered on the Synaptic
Leap indicating that they are actively participating or are
interested in participating in research for schistosomiasis. Thirty-
seven (37) contributed to the TSLS project. The contributors
include six members of Todd’s team, four industry representatives,
15 academics/researchers, one retiree, two informatics profession-
als, and 9 of unknown affiliation. Contributors were based in
Africa, Europe, Oceania and North America. Only one postdoc-
toral researcher from the University of Sydney was paid
specifically to work on the project. Motivations for participation
included accelerating own research, intellectual stimulation,
signaling abilities and a belief in the benefits of open collaboration.
Their contributions ranged from one-off comments regarding the
project to substantial postings regarding laboratory results.
Management of Intellectual Property
TSLS places all scientific discoveries in the public domain,
therefore, obviating the ability to patent them. All of the website
content is copyright protected according to the Creative Com-
mons Attribution 2.5 License unless otherwise stipulated [56]. All
content may be viewed without a username and password. If an
individual wants to make a posting on the Synaptic Leap website,
he/she can either leave a comment as a guest or as a registered
user. A guest must supply a valid e-mail address which is not
viewable with the comment. Registering requires a username and
e-mail address. An automated system sends a log-on password.
There is no requirement to accept a license at time of registration.
Intellectual property does not play a major role in this project
since a version of praziquantel has been in the public domain for
almost two decades.
Progress
The scope of this project was limited to a specific problem.
Once they managed to generate a single enantiomer of
praziquantel, the expectation was that the project would be
complete (although the project continues looking at more elegant
solutions to the problem). The next steps of scaling up the modified
drug to commercial quantities and any regulatory approvals
needed would be performed externally by a pharmaceutical
manufacturer in partnership with WHO.
Funding
Funding was important to the project because it allowed for the
recruitment of a full-time postdoctoral researcher whose postings
provided fresh, regular content giving the project momentum. The
grant money paid the salary of the postdoctoral student, all
administrative supplies and covered the cost of shipping the
samples to any interested laboratory. Contributing organizations
did not receive any monies from the project.
Comparative Analysis: CSIR OSDD and TSLS
Firstly, we would like to acknowledge that both cases have made
great accomplishments in meeting their aims. CSIR OSDD has
persuaded a large number of volunteers to contribute and
published four articles in 2011, a significant accomplishment for
a group of volunteers. TSLS has gathered contributors from
around the globe, both from academia and the private sector and
has managed to fulfill its goal.
The two cases operate very differently and differ greatly in
magnitude. CSIR OSDD is a vast project, encouraging interna-
tional collaboration on its website, but in actuality, geared
principally towards Indian researchers and students. The funding
from the Indian government applies only to activities within India
[24]. There are many workshops and face-to-face meetings in
India as well as private e-mail correspondence between teacher
and pupil. This, in essence, translates into an Indian-centric
project. TSLS, on the other hand, has attracted contributors
internationally, albeit substantially fewer than CSIR OSDD, with
a variety of motivations. Both have obtained funding used to pay
for access to facilities, physical resources and, at times, labor costs.
TSLS releases its results into the public domain, where as CSIR
OSDD asserts ownership over its results.
If we return to R4D’s definition of open source – the application
of open access, open collaboration and open rules – it is useful to
analyze each case’s adherence to the definition in order to
understand the impact of this adherence (see Table 4).
CSIR OSDD’s scientific research results are placed on Sysborg
which requires a user to log on before any content may be viewed.
The content is not searchable through general search engines like
Google. Technically, the content is open access because a
username and password are eventually granted to users allowing
them to view the data free-of-charge. However, we believe that
this tight control of the data is actually a barrier to entry. Most
potential contributors will want to browse the website before
contributing, and they may lose interest in the two days or more
that it takes to receive access to the full content. Indeed, a few
TSLS contributors reported through the interviews that they had
tried to access CSIR OSDD and had given up in frustration. CSIR
OSDD’ process limits contributors to only those who have a strong
motivation to contribute.
CSIR OSDD has assigned certain tasks to partner institutions.
This is likely a practical solution to achieving progress. These
institutions receive funding and have commitments back to CSIR
OSDD. They must follow an agreed structure and process. Other
institutions or individuals can no doubt assist in any activity.
However, since much of the process is opaque (through face-to-face
meetings, Skype or private e-mail) and not reported back through
Sysborg, open collaboration is difficult. This opaqueness does not
promote cross-organizational or geographical linkages. Until the
processes and decision-making are made more transparent and
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for open collaboration.
CSIR OSDD’s license awards the project ownership over all
data. Data may not be used by other entities without entering into
a contract with CSIR OSDD. The license may also be considered
viral since all improvements based upon CSIR OSDD data are to
be granted back to CSIR OSDD (i.e. future generations of
improvements are subject to the CSIR OSDD license if any of the
original CSIR OSDD data was used). This may make industry shy
away from participating in the project. CSIR OSDD has taken a
very protective approach of its data likely so that it is not
expropriated and exploited by a third party. This is understand-
able considering the potential commercial value of new tubercu-
losis medicines. However, CSIR OSDD’s license does therefore
not mandate ‘‘openness’’. CSIR OSDD states that the project will
shepherd its new products up through regulatory approval and
then make them available to the generic drug industry without any
exclusivity [24]. It is unclear whether they intend to patent the
drugs and offer a non-exclusive license to generic manufacturers,
utilize the public domain or an alternative intellectual property
strategy. Perhaps they have not yet decided themselves. The
license language, however, does not mandate openness.
We believe that rather than a strictly defined open source
project, CSIR OSDD is actually a highly successful crowdsourcing
project, using volunteers to perform specified and structured tasks.
They have achieved most of the advantages of open source
identified by R4D. The data results are verified (although offline),
but the project’s impressive publishing demonstrates that its work
has passed peer review muster. The contributions of 400+
volunteers result in a significant cost savings. Undoubtedly, any
medicines that they develop will enter the market at a low price
point. They have not, however, succeeded in creating open
collaboration or a public commons of knowledge. They have
created a proprietary knowledge repository.
TSLS is largely in adherence to the open source drug discovery
definition. All of TSLS’ data are publicly-available without a
password. Searches within Google for related TSLS content return
all of TSLS’ related websites. This makes it easy for potential
contributors to firstly find the project and then browse the content
to get a feeling for the project. However, TSLS’ website could also
be improved. Postings are not necessarily in chronological order
and there is no easy method to see all postings related to one
disease area. Thanks to TSLS’ project manager’s continuous
efforts to summarize the current state of play, these inconveniences
are minimized.
TSLS’ websites allow for open collaboration across organiza-
tional and geographical boundaries. It is stressed that e-mails
should be avoided. Raw data is placed directly on the website
awaiting virtual peer review. Observers can easily follow the
threads of the process.
TSLS uses well known legal concepts with the public domain
and a creative commons license. Both mandate ‘‘openness’’.
Results may be utilized by third parties without contracts or
royalties.
TSLS has achieved all of the open source advantages. Its
content is transparently verified on the website with the additional
peer review of publishing in top-ranked journals. The data forms a
knowledge commons. Global collaboration was achieved between
representatives from both academia and industry. The grant
funding and volunteer contributions of industry significantly sped
up the progress of the project, achieving cost savings.
Discussion
These two cases demonstrate that drug innovation can be
performed using an open source approach, albeit in very different
ways and not necessarily in strict adherence to the definition of
open source drug discovery. Adherence to the definition is not
necessarily that important. As a crowdsourced project, CSIR
OSDD has still achieved great success by persuading volunteers to
perform high quality research at low cost, which, of course, is the
goal of open source collaboration. The definition is still useful
though, to evaluate how different projects approach transparency,
collaboration and access to results, but not necessary to spur on
high quality, low cost drug discovery. The cases do point to three
common critical success factors: clearly defined entry points,
transparency and funding.
Both projects attracted volunteers by publicizing the respective
projects through descriptive articles in academic journals and
utilizing social media and networks. CSIR OSDD has also
effectively paired up with Indian universities and colleges,
incentivizing students to volunteer as parts of classroom assign-
ments or positioning participation as valuable hands-on experi-
ence. They have also built in an element of patriotism, linking
finding cures for tuberculosis as an Indian responsibility due to the
high prevalence of tuberculosis in India. This patriotic effect is
reinforced through project marketing efforts, like the project’s
music video [57]. The entry point into CSIR OSDD is through
the classroom which is likely to limit international participation in
the project. Rather TSLS’ entry point is through the website, using
frequent status updates to pinpoint exactly the tasks currently
needed.
The two cases approach collaboration and progress in different
ways. TSLS takes a very transparent approach, posting raw data,
containing the discussion to publicly-available websites and
placing results in the public domain. CSIR OSDD takes a more
cautious approach with a significant amount of work being
performed through face-to-face or Skype meetings, greater use of
private e-mail exchanges and a license that emphasizes mostly
trust in the project’s mission rather than legally-binding clauses
stipulating open access to the data.
Funding was an absolute necessity for both projects. Without it,
they would not have been able to access the laboratories and
physical supplies needed for drug innovation, hire the minimum
number of employees needed to give the projects their initial
momentum, or perform routine administrative functions (such as
website hosting). How much savings each project has achieved
through the use of volunteers is uncertain. The Global Alliance for
TB Drug Development calculated in 2001 that the estimated costs
Table 4. Are the cases open source?
Open Access Open Collaboration Open Rules
CSIR OSDD Yes, but only with significant effort No No
TSLS Yes Yes Yes
doi:10.1371/journal.pntd.0001827.t004
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(including the costs of failure) where between US$115 million
and US$240 million [58]. CSIR OSDD has about US$35 million
at its disposal but they are still in early days, having yet to embark
upon the most expensive part of the process, clinical trials. Maurer
[59] in 2005 estimated that lead compound optimization costs
between millions to tens of millions of US dollars. The chemists
from TSLS achieved their result with about US$330,000.
However, they were working with a known, effective lead
compound with a specific problem.
The results of this case study cannot be generalized to all open
source drug discovery projects since we only examined two,
separate efforts. However, we believe that our findings are relevant
to other projects interested in the open source model. Firstly, the
cases give an indication of the number of participants necessary to
achieve different drug discovery tasks. TSLS managed to complete
its task with a relatively modest 37 individuals, with only a few of
these dedicating large amounts of time to the project. On the other
hand CSIR OSDD will require hundreds of contributors to
discover and develop a new tuberculosis medicine.
The market realities of the potential drugs may also play a role
in a project’s adherence to the strict definition of open source.
CSIR OSDD has reasonable grounds for protecting their data
through a gated community and a protective license, namely that
new tuberculosis products offer private companies with a profit
potential in both developed and developing countries, especially
lucrative if they have not had to invest in R&D. The public
domain is not actually an intellectual property right but the absence
of one. If a patent were to be granted to others on the knowledge
developed by CSIR OSDD, the only way to defend against that
claim would be a costly court trial. One can therefore argue that
CSIR OSDD has utilized a protective license as a negative
measure to safeguard others trying to patent the knowledge. In
contrast the risk that TSLS’ version of praziquantel will be
expropriated and patented is next to null since schistosomiasis is
only endemic to developing countries and the generic form of
praziquantel is already available cheaply.
Unfortunately our case study is weakened by a rather low
interview response rate from the CSIR OSDD project. We
surmise that our timing was unlucky as an article critical of the
project appeared just before we started recruitment [60]. This
paper criticized the project for not publishing its first results in a
peer-reviewed journal. A few potential interviewees expressed
skepticism that we did not harbor an ulterior, negative motive. We
debated the benefits of offering a cash prize to gather additional
respondents but decided that this may only fuel the skepticism
surrounding our study. We attempted to compensate by closely
examining the content on the websites including interactions and
self-reported data. We also submitted our results to the project
manager of each of the two cases and incorporated their feedback
into the final paper.
Are CSIR OSDD and TSLS model cases for open source drug
discovery? It is too early to tell. Since there are so few instances of
open source drug discovery, the model is still being developed,
most recently with an interesting new joint project between TSL
and CSIR OSDD with a focus on malaria initiated in 2011 [61].
More modeling is still needed, especially in evaluating the
potential of hybrid models that combine open source with
standard intellectual property mechanisms like data exclusivity
and secrecy. Interesting examples (like the public-private partner-
ship, the Archipelago to Proof of Clinical Mechanism [62]) are
combining these approaches in the areas of neurology and
oncology.
The recently released report of WHO’s Consultative Expert
Working Group on R&D Financing and Coordination [5] has
called for greater use of ‘‘open knowledge innovation’’. This
concept is more general than open source and groups open source
drug discovery with equitable licensing, patent pools and prizes (in
other words, creating a grouping of the drug discovery and access
business models with a primary focus of sharing of open
knowledge, particularly to meet the needs of low-income
countries). As organizations consider acting on the expert group’s
recommendations, and possibly funding organizations begin
requiring a certain level of adherence to the open source model,
the model will become more mainstream, giving a new level of
transparency and access to the data needed to more efficiently
finding cures for neglected diseases.
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